

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In the Patent Application of

DAVIS et al.

Serial No. 09/897,412



Atty Dkt. 620-148

C# M#

Group Art Unit: 1743

Examiner:

Filed: July 3, 2001

Date: November 23, 2001

Title: USE OF SECRETIN-RECEPTOR LIGANDS IN TREATMENT OF CYSTIC FIBROSIS (CF) AND CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD)

Assistant Commissioner for Patents

Washington, DC 20231

Sir:

RESPONSE/AMENDMENT/LETTER

This is a response/amendment/letter in the above-identified application and includes an attachment which is hereby incorporated by reference and the signature below serves as the signature to the attachment in the absence of any other signature thereon.

Fees are attached as calculated below:

Total effective claims after amendment	0	minus highest number		
previously paid for	20	(at least 20) =	0	x \$ 18.00
				\$ 0.00

Independent claims after amendment	0	minus highest number		
previously paid for	3	(at least 3) =	0	x \$ 84.00
				\$ 0.00

If proper multiple dependent claims now added for first time, add \$280.00 (ignore improper)		\$ 0.00
--	--	---------

Petition is hereby made to extend the current due date so as to cover the filing date of this paper and attachment(s) (\$110.00/1 month; \$400.00/2 months; \$920.00/3 months)		\$ 0.00
--	--	---------

Terminal disclaimer enclosed, add \$ 110.00		\$ 0.00
---	--	---------

<input type="checkbox"/> First/second submission after Final Rejection pursuant to 37 CFR 1.129(a) (\$740.00)		\$ 0.00
<input type="checkbox"/> Please enter the previously unentered , filed		
<input type="checkbox"/> Submission attached		

Subtotal	\$ 0.00
-----------------	----------------

If "small entity," then enter half (1/2) of subtotal and subtract		-\$ 0.00
<input type="checkbox"/> Applicant claims "small entity" status. <input type="checkbox"/> Statement filed herewith		

Rule 56 Information Disclosure Statement Filing Fee (\$180.00)		\$ 0.00
--	--	---------

Assignment Recording Fee (\$40.00)		\$ 0.00
------------------------------------	--	---------


Other: Information Disclosure Statement, PTO-1449, references and search report; Statement with paper and computer-readable copies of Sequence Listing; copy of Notice to Comply dated 10/22/01 ; Copy of Withdrawal dated 10/22/01		\$ 0.00
---	--	---------

TOTAL FEE ENCLOSED	\$ 0.00
---------------------------	----------------

The Commissioner is hereby authorized to charge any deficiency in the fee(s) filed, or asserted to be filed, or which should have been filed herewith (or with any paper hereafter filed in this application by this firm) to our Account No. 14-1140. A duplicate copy of this sheet is attached.

1100 North Glebe Road, 8th Floor
 Arlington, Virginia 22201-4714
 Telephone: (703) 816-4000
 Facsimile: (703) 816-4100
 BJS:eaw

NIXON & VANDERHYE P.C.
 By Atty: B. J. Sadoff, Reg. No. 36,663

Signature: 

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of

DAVIS et al.

Serial No.

09/897,412

Filed: July 3, 2001



Atty. Ref.: 620-148

Group: 1743

Examiner:

For: **USE OF SECRETIN-RECEPTOR LIGANDS IN
TREATMENT OF CYSTIC FIBROSIS (CF) AND CHRONIC
OBSTRUCTIVE PULMONARY DISEASE (COPD)**

November 23, 2001

Assistant Commissioner for Patents
Washington, DC 20231

Sir:

AMENDMENT

Responsive to the Notice to Comply dated October 22, 2001 (copy attached),
entry and consideration of the following amendments and remarks are requested.

IN THE SPECIFICATION

Amend the specification as follows.

Page 13, delete the paragraph spanning lines 8-28, and insert the following
therefor:

--For example, Gespach et al (1986) describe four synthetic secretin analogues including one corresponding to porcine secretin substituted at the N-terminus by sequence portions of vasoactive intestinal peptide (VIP), i.e. Ala4-Val5-pSN, together with Tyr1-Ala2-Glu3-pSN, Gln3-pSN, Phe1-Phe2-Trp3-Lys4-pSN (SEQ ID NO:13). Konig et al (1977) describe Ala4-pSN. Gardener et al (1976) describe the secretin fragment